Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR).

Böldicke T, Weber H, Mueller PP, Barleon B, Bernal M.

J Immunol Methods. 2005 May;300(1-2):146-59. Erratum in: J Immunol Methods. 2005 Aug;303(1-2):153-4.

PMID:
15946674
2.

Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.

Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, Barbas CF 3rd.

J Biol Chem. 2003 Nov 28;278(48):47812-9. Epub 2003 Aug 28.

3.

Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis.

Wheeler YY, Kute TE, Willingham MC, Chen SY, Sane DC.

FASEB J. 2003 Sep;17(12):1733-5. Epub 2003 Jul 3.

4.

Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.

Li R, Xiong DS, Shao XF, Liu J, Xu YF, Xu YS, Liu HZ, Zhu ZP, Yang CZ.

Acta Pharmacol Sin. 2004 Oct;25(10):1292-8.

6.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2003 Oct 31;278(44):43496-507. Epub 2003 Aug 12.

7.

Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.

Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, Zhu Z.

Leuk Lymphoma. 2004 Sep;45(9):1887-97.

PMID:
15223651
8.

Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.

Ryu J, Lee CW, Hong KH, Shin JA, Lim SH, Park CS, Shim J, Nam KB, Choi KJ, Kim YH, Han KH.

Cardiovasc Res. 2008 May 1;78(2):333-40. Epub 2007 Nov 11.

9.

Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.

Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.

Life Sci. 2006 Nov 17;79(25):2370-81. Epub 2006 Aug 16.

PMID:
16959272
10.

Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus.

Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S, Perrot-Applanat M.

J Endocrinol. 2006 Jan;188(1):91-9.

11.

Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening.

Zhong L, Guo XN, Zhang XH, Wu ZX, Luo XM, Jiang HL, Lin LP, Zhang XW, Ding J.

Biochim Biophys Acta. 2005 Apr 15;1722(3):254-61. Epub 2005 Jan 13.

PMID:
15715968
12.

[Effect of monoclonal antibody against extracellular domain III of vascular endothelial growth factor receptor KDR on proliferation of vascular endothelial cells].

Li R, Xiong DS, Shao XF, Xu YF, Zhu ZP, Yang CZ.

Zhonghua Zhong Liu Za Zhi. 2005 Apr;27(4):209-12. Chinese.

PMID:
15949417
13.

Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.

Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y, Guo QL.

Biochem Biophys Res Commun. 2007 Sep 14;361(1):79-84. Epub 2007 Jul 10.

PMID:
17644065
14.

[Effect of recombinant VEGF-C secreted from eukaryotic cells on proliferation and chemotherapy-induced apoptosis of leukemic cells].

Ding KY, Bai X, Dai L, Dong NZ, Ruan CG.

Ai Zheng. 2005 Sep;24(9):1037-42. Chinese.

PMID:
16159421
15.

VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing.

Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, Dias S.

Exp Cell Res. 2007 May 1;313(8):1561-74. Epub 2007 Mar 1.

PMID:
17382929
16.

Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.

Nishi J, Minamino T, Miyauchi H, Nojima A, Tateno K, Okada S, Orimo M, Moriya J, Fong GH, Sunagawa K, Shibuya M, Komuro I.

Circ Res. 2008 Aug 1;103(3):261-8. doi: 10.1161/CIRCRESAHA.108.174128. Epub 2008 Jun 26.

17.

Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.

Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K.

J Biol Chem. 2006 Apr 28;281(17):12187-95. Epub 2006 Feb 27.

18.
19.

A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.

Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS.

Mol Cancer Res. 2004 Jun;2(6):315-26.

20.
Items per page

Supplemental Content

Write to the Help Desk